Abiomed Announces Q1 FY 2019 Record Revenue of $180 Million, Up 36% Over Prior Year
Completed Enrollment for the FDA STEMI DTU Safety and Feasibility Study
DANVERS, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- ABIOMED, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported first quarter fiscal 2019 revenue of $180.0 million, an increase of 36% compared to revenue of $132.5 million for the same period of fiscal 2018. First quarter fiscal 2019 GAAP net income was $90.1 million or $1.95 per diluted share, up 141% compared to GAAP net income of $37.4 million or $0.82 per diluted share for the prior year period.
Recent financial and operating highlights include:
- Worldwide Impella® heart pump revenue for the quarter totaled $173.7 million, an increase of 37% compared to revenue of $127.2 million during the same period of the prior fiscal year.
- U.S. Impella heart pump revenue for the quarter totaled $151.7 million, an increase of 32% compared to revenue of $114.7 million during the same period in the prior fiscal year with U.S. patient usage of the Impella heart pumps up 30%.
- Outside the U.S., Impella heart pump revenue for the quarter totaled $21.9 million, an increase of 75% compared to revenue of $12.5 million during the same period in the prior fiscal year.
- Gross margin for first quarter 2019 was 82.9% compared to 83.5% during the same period in the prior fiscal year.
- Operating income for the first quarter was $46.7 million, or 26.0% operating margin, compared to $33.1 million, or 25.0% operating margin in the prior fiscal year.
- First quarter fiscal 2019 GAAP net income was $90.1 million, or $1.95 per diluted share, which benefited from $53.8 million, or $1.17 per diluted share, of excess tax benefits related to employee share-based compensation awards recorded as a reduction of income tax expense. This compared to GAAP net income of $37.4 million or $0.82 per diluted share for the prior fiscal year, which benefited from $16.8 million, or $0.37 per diluted share, of excess tax benefits.
- The Company's cash and marketable securities balance as of June 30, 2018 was $367.4 million. The Company currently has no debt.
- In June 2018, the Company completed enrollment for its STEMI DTU safety and feasibility study and 30-day follow-up.
- In June 2018, the Company received approval in India for Impella 2.5®, Impella CP® and Impella 5.0® and treated the first patient at Fortis Escorts Heart Institute in New Delhi.
- On June 22, 2018, the Company held the inaugural Women's Initiative for Heart Recovery Physician Advisory Board meeting. Physicians collaborated to raise awareness of the expanded FDA indications for Impella for patients with peripartum and postpartum cardiomyopathy (PPCM) and spontaneous coronary artery dissection (SCAD).
"Abiomed reported a strong start to our fiscal year 2019," said Michael R. Minogue, Chairman, President and Chief Executive Officer, ABIOMED, Inc. "Abiomed is committed to sustainable growth and improving patient outcomes each quarter. We do this through advanced training, product enhancements and sharing of best practices derived from real world experience."
FISCAL YEAR 2019 OUTLOOK
The Company is increasing the lower end of its fiscal year 2019 revenue guidance by $15 million to a new range of $755 million to $770 million, an increase of 27% to 30% over the prior fiscal year. The Company is maintaining its fiscal year 2019 guidance for GAAP operating margin in the range of 28% to 30%.
EARNINGS CONFERENCE CALL DETAILS
The Company will host a conference call to discuss the results at 8 a.m. ET on Thursday, July 26, 2018. The conference call releasing full quarterly results will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd A. Trapp, Vice President and Chief Financial Officer.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. ET July 26, 2018 through 11:00 a.m. ET on August 2, 2018. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 295-7159.
The ABIOMED logo, ABIOMED, IMPELLA, IMPELLA 2.5, IMPELLA 5.0, IMPELLA LD, IMPELLA CP, IMPELLA RP, IMPELLA BTR, IMPELLA 5.5, and IMPELLA ECP are registered marks or trademarks of ABIOMED, Inc., and are registered in the U.S. and certain foreign countries. AB5000 and cVAD REGISTRY, Recovering hearts. Saving lives. are trademarks of ABIOMED, Inc.
Based in Danvers, Massachusetts, ABIOMED, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com
This release contains forward-looking statements, including statements regarding development of ABIOMED's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
For further information please contact:
Director, Investor Relations
|Abiomed, Inc. and Subsidiaries|
|Consolidated Balance Sheets|
|(in thousands, except share data)|
|June 30, 2018||March 31, 2018|
|Cash and cash equivalents||$||61,288||$||42,975|
|Short-term marketable securities||299,228||319,274|
|Accounts receivable, net||67,511||70,010|
|Prepaid expenses and other current assets||13,489||11,808|
|Total current assets||497,297||494,271|
|Long-term marketable securities||6,887||37,502|
|Property and equipment, net||127,324||117,167|
|In-process research and development||15,837||16,705|
|Long-term deferred tax assets, net||115,049||70,746|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Total current liabilities||76,678||84,682|
|Other long-term liabilities||815||776|
|Long-term deferred tax liabilities||856||903|
|Commitments and contingencies|
|Class B Preferred Stock, $.01 par value||-||-|
|Authorized - 1,000,000 shares; Issued and outstanding - none|
|Common stock, $.01 par value||449||444|
|Authorized - 100,000,000 shares; Issued - 46,767,984 shares at June 30, 2018 and 46,100,649 shares at March 31, 2018|
|Outstanding - 44,876,271 shares at June 30, 2018 and 44,375,337 shares
at March 31, 2018
|Additional paid in capital||637,974||619,905|
|Treasury stock at cost - 1,891,713 shares at June 30, 2018 and 1,725,312 shares at March 31, 2018||(134,674||)||(67,078||)|
|Accumulated other comprehensive loss||(10,913||)||(4,204||)|
|Total stockholders' equity||723,359||689,524|
|Total liabilities and stockholders' equity||$||812,039||$||786,375|
|Abiomed, Inc. and Subsidiaries|
|Consolidated Statements of Operations|
|(in thousands, except per share data)|
Three Months Ended
|Costs and expenses:|
|Cost of product revenue||30,850||21,862|
|Research and development||21,273||16,931|
|Selling, general and administrative||81,139||60,597|
|Income from operations||46,748||33,078|
|Investment income, net||1,551||635|
|Other income, net||188||79|
|Income before income taxes||48,487||33,792|
|Income tax benefit (1)||(41,579||)||(3,582||)|
|Basic net income per share||$||2.02||$||0.85|
|Basic weighted average shares outstanding||44,546||43,895|
|Diluted net income per share (2)||$||1.95||$||0.82|
|Diluted weighted average shares outstanding||46,169||45,608|
|(1) Income tax benefit includes the effect of the following item:|
|Excess tax benefits related to stock-based compensation awards||$||53,837||$||16,842|
|(2) Diluted net income per share includes the effect of the following item:|
|Excess tax benefits related to stock-based compensation awards||$||1.17||$||0.37|
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Province Brands of Canada Announces Proposed Reverse Takeover of Colson Capital Corporation25.9.2018 00:56 | Pressemelding
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. CALGARY, Alberta, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Colson Capital Corp. (“Colson” or the “Corporation”) (TSXV: COLS.P) and Honest Inc., dba Province Brands of Canada (“Province Brands”), are pleased to announce that they have entered into an amended and restated arrangement agreement dated September 17, 2018 (the “Arrangement Agreement”) in respect of their proposed business combination transaction (the “Proposed Transaction”) which was previously announced in the news release of the Corporation dated June 5, 2018. The Proposed Transaction is expected to constitute Colson’s Qualifying Transaction under Policy 2.4 – Capital Pool Companies (“Policy 2.4”) of the TSX Venture Exchange (the “Exchange” or “TSXV”), subject to the TSXV’s approval. It is expected that the Resulting Issuer (as defined below) wil
Northland Power Opens Offshore Wind Operations Hub in Germany24.9.2018 23:30 | Pressemelding
New organizations support Northland’s expanded capabilities TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced the opening of its offshore wind operations hub in Germany. The hub represents an expansion of Northland’s focus on offshore wind operations. Initial activities are focused on achieving synergies across the 332 MW Nordsee One wind farm, which commenced commercial operations in 2017, and the 269 MW Deutsche Bucht project, which is currently in construction. The team will also support Northland’s global project development work. Operations and maintenance activities, including remote monitoring and control of the wind turbines and substations, have been centralized in a port-side facility in the village of Norddeich. Commercial and engineering activities are being managed from a new office in the Hamburg area. “I’m pleased to welcome the Northland team to their new headquarters,” noted Troy Patton, Chief Ope
Concord Technologies Unveils NEXTSTEP—AI-driven, Cloud-based Platform that Simplifies Patient Data Capture and Document Workflows24.9.2018 23:12 | Pressemelding
SEATTLE, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Concord Technologies, a leading provider of cloud fax services and document process automation solutions, today launched NEXTSTEP, a new, AI-driven, cloud-based platform optimized for healthcare providers to reduce the effort required to capture, access and integrate patient health information from paper and digital documents. Concord has optimized NEXTSTEP for healthcare providers struggling to digitize document-intensive clinical workflows, though its core features apply across all highly-regulated industries. Unlike conventional systems, NEXTSTEP is pre-trained to identify, classify and extract specific, field-level data, so it saves providers the cost and effort to “teach” the system what to look for. It also extends automated document classification and routing with the ability to coordinate document handling even with frequently-changing clinical processes. “We estimate a sizable market of providers who are being underserved by conventi
The Connecticut Institute for Refugees and Immigrants honors Ethan Allen’s Farooq Kathwari24.9.2018 23:00 | Pressemelding
DANBURY, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- The Connecticut Institute for Refugees and Immigrants (CIRI) honored Farooq Kathwari, Chairman, President and CEO of Danbury-based Ethan Allen Interiors Inc., with its Legacy Award at a gala dinner in Westport, CT., on September 23. He was chosen for this honor in recognition of his commitment to humanitarian causes, to justice and human dignity, and to the plight of displaced people across the world. Mr. Kathwari has served in numerous capacities at many nonprofit organizations; among them, he is currently a member of the Board of Overseers of the International Rescue Committee, and a chairman emeritus of Refugees International. The gala commemorated CIRI's 100 years as the state’s leading champion for refugees, immigrants, survivors of torture, and survivors of human trafficking. Founded in 1918 as the International Institute of Connecticut (IICONN), CIRI remains the state’s preeminent provider of advocacy and high-impact services th
Constellation Brands Elects Jennifer M. Daniels of Colgate-Palmolive Company to its Board of Directors24.9.2018 22:07 | Pressemelding
VICTOR, N.Y., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today the election of Jennifer M. Daniels, chief legal officer and secretary of Colgate-Palmolive Company, to serve as a member of its board of directors, effective as of the close of business on September 20, 2018. This election increases the size of Constellation’s board from 11 to 12 members. “We are pleased to welcome Jennifer to our board of directors,” said Constellation’s Chairman of the Board Richard Sands. “Jennifer brings extensive experience in consumer product goods, mergers and acquisitions, regulatory compliance and corporate governance that will serve as tremendous assets to our board at a very exciting time as our company explores new avenues of growth, while continuing to build momentum for our high-performing beverage alcohol business.” Since November 2014, Daniels has served as chief legal officer and secretary of Colgate-Pa
World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival24.9.2018 20:26 | Pressemelding
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival. IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-l
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom